GlassScriptPhysician profile
Jeet D Joshi
NPI 1356634901
$4,657.83
in general payments reported to CMS, 2019-2025
24 companies · $778 in 2025
The $778 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $318 · 2021: $694 · 2022: $990 · 2023: $878 · 2024: $774 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $563.24 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $539.58 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $505.76 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $428.36 | 2019-2025 | Invega, Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $349.96 | 2019-2022 | |
| Corium, LLC | $348.21 | 2023-2024 | Azstarys |
| Lundbeck LLC | $310.81 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $295.98 | 2022-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $215.70 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $205.95 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $129.98 | 2021-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $123.81 | 2019-2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $105.26 | 2021-2022 | |
| Eisai INC. | $90.31 | 2021-2022 | |
| Axsome Therapeutics, INC. | $79.36 | 2023-2025 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $68.28 | 2020-2024 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $65.71 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $57.71 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $49.42 | 2020-2021 | |
| Noven Therapeutics, LLC | $48.68 | 2024 | Xelstrym |
| Tris Pharma INC | $20.93 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.56 | 2021 | |
| Braeburn INC. | $18.79 | 2024 | Brixadi |
| Almatica Pharma LLC | $16.48 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeet Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.